Public Citizen Seeks To Hold Up Lilly Prasugrel Review For Further Data
Executive Summary
Public Citizen's decision to file a citizen petition June 3 asking FDA to halt its review of Lilly/Daiichi Sankyo's prasugrel suggests the watchdog group may believe the agency is on the verge of approving the platelet inhibitor
You may also be interested in...
Does TRITON Really Show If Effient Was Better Than Plavix?
The pivotal TRITON-TIMI 38 trial supporting the approval of Lilly/Daiichi Sankyo's Effient (prasugrel) was a lot of things that FDA likes: big (nearly 14,000 patients), long (a median 14.5 months of treatment) and clearly focused on clinical outcomes (the primary endpoint was a composite of cardiovascular death, non-fatal MI, and non-fatal stroke)
Does TRITON Really Show If Effient Was Better Than Plavix?
The pivotal TRITON-TIMI 38 trial supporting the approval of Lilly/Daiichi Sankyo's Effient (prasugrel) was a lot of things that FDA likes: big (nearly 14,000 patients), long (a median 14.5 months of treatment) and clearly focused on clinical outcomes (the primary endpoint was a composite of cardiovascular death, non-fatal MI, and non-fatal stroke)
Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role
FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA